IGF-I assays: current assay methodologies and their limitations.

IGF-I assays: current assay methodologies and their limitations. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

IGF-I assays: current assay methodologies and their limitations. Abstract Text:

David R Clemmons,David R Clemmons,

The diagnosis of disorders of growth hormone (GH) is dependent upon accurate measurement of insulin-like growth factor-I (IGF-I) concentrations since serum IGF-I assays have been found to be useful as a screening tests for the presence of growth hormone deficiency (GHD) in children and in both children and adults they have been found very useful in establishing the diagnosis of acromegaly. IGF-I is also used extensively to monitor the response to GH treatment in children and adults and to monitor the response to treatment in acromegaly. Since IGF-I is influenced by several other hormones and physiologic factors as well as GH, a knowledge of its regulation is essential to understanding how to properly interpret the measurements. Several technical criteria are required for successful laboratory estimation of IGF-I values. These include elimination of interference of IGF-I-binding proteins (IGFBP), utilization of adequate numbers of normal subjects to define the normal ranges and importantly the use of high affinity, high specificity antisera that allow precise and reproducible measurements of the biologically active peptide. Cross comparisons of various commercial assays show that the results generally are similar when values are in the normal range. However, the assays have different performance characteristics when concentrations are either above or below the normal range. To obtain cross laboratory standardization for values outside the normal range requires utilization of similar, high-quality reagents and techniques that are reasonably comparable. Without this degree of standardization, cross comparisons among various reference laboratories are likely to continue to show wide divergence for values that are above or below the 95% confidence interval. A future goal should be the development of standard procedures and reagents that eliminate this degree of variability.

IGF-I assays: current assay methodologies and their limitations. Publishing Authors By Initials

DR Clemmons,DR Clemmons,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

IGF-I assays: current assay methodologies and their limitations. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Pituitary

VOLUME: 10

Page Numbers: 121-8

Journal Abbreviation: Pituitary

ISSN: 1386-341X

DAY: 25

MONTH: 05

YEAR: 2007

IGF-I assays: current assay methodologies and their limitations. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 9814578

IGF-I assays: current assay methodologies and their limitations. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: IGF-I assays: current assay methodologies and their limitations. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for IGF-I assays: current assay methodologies and their limitations.

AFFILIATION: CB# 7170, 8024 Burnett-Womack, Division of Endocrinology, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599-7170, USA, endo@med.unc.edu.

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Pituitary

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

IGF-I assays: current assay methodologies and their limitations Related Publications

• Bilateral fractures of the head of the humerus; due to electric shock.
• Detection of oligoclonal bands in cerebrospinal fluid from German Shepherd dogs with degenerative myelopathy by isoelectric focusing and immunofixation.
• Expression of the human beta3 integrin subunit in mouse smooth muscle cells enhances IGF-I-stimulated signaling and proliferation.
• Glucose regulation of integrin-associated protein cleavage controls the response of vascular smooth muscle cells to insulin-like growth factor-I.
• Hyperglycemia alters the responsiveness of smooth muscle cells to insulin-like growth factor-I.
• IGF-I assays: current assay methodologies and their limitations.
• Insulin-like Growth Factor-I Stimulates Shc-dependent Phosphatidylinositol 3-Kinase Activation via Grb2-associated p85 in Vascular Smooth Muscle Cells.
• Insulinlike growth factor binding proteins.
• Integrin-associated protein association with SRC homology 2 domain containing tyrosine phosphatase substrate 1 regulates igf-I signaling in vivo.
• Long-acting forms of growth hormone-releasing hormone and growth hormone: effects in normal volunteers and adults with growth hormone deficiency.
• Measurement of myelin basic protein in the cerebrospinal fluid of dogs with degenerative myelopathy.
• Modulation of integrin antagonist signaling by ligand binding of the heparin-binding domain of vitronectin to the alphaVbeta3 integrin.
• Protease-resistant form of insulin-like growth factor-binding protein 5 is an inhibitor of insulin-like growth factor-I actions on porcine smooth muscle cells in culture.
• Protease-resistant insulin-like growth factor (IGF)-binding protein-4 inhibits IGF-I actions and neointimal expansion in a porcine model of neointimal hyperplasia.
• Regulatory Actions of Insulin-like Growth Factor-binding Proteins.
• Sports Injuries among U.S. Army Soldiers Deployed for Operation Iraqi Freedom: 2182: Board #95 June 1 8:00 AM -9:30 AM.
• The surgical treatment of fractures of the lateral tibial condyle.
• Value of insulin-like growth factor system markers in the assessment of growth hormone status.
• p66shc Negatively Regulates Insulin-Like Growth Factor I Signal Transduction via Inhibition of p52shc Binding to Src Homology 2 Domain-Containing Protein Tyrosine Phosphatase Substrate-1 Leading to Impaired Growth Factor Receptor-Bound Protein-2 Membrane